# Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)

> **NCT02831088** · PHASE2 · UNKNOWN · sponsor: **GNT Pharma** · enrollment: 210 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Neu2000KWL High-does group
- **DRUG:** Neu2000KWL Low-does group
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02831088
- **Lead sponsor:** GNT Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2018-12-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831088, "Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02831088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*